Drug
Delgocitinib clinical trials
Also written LEO 124249.
- studies test it
- 26
- open now
- 6
- in phase 3
- 7
- first study started
- 2016
Keep track of what changes. Save the delgocitinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Combined with it in one product
Studies by the year they started
26 studies that test it; most in 2026 (6)
| Year | Studies |
|---|---|
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 5 |
| 2022 | 4 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 4
- Phase 2
- 13
- Phase 3
- 7
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 21 · Other 5
LEO Pharma (21) · Lone Skov (1) · Maryanne Makredes Senna (1) · Aarhus University Hospital (1) · Aalborg University (1) · Icahn School of Medicine at Mount Sinai (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses delgocitinib is read from its arms, and is right about nine times in ten.
Testing it · 26
- A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen SclerosusRecruitingPhase 3LEO PharmaNCT07335588Written as Delgocitinib
- A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar PustulosisRecruitingPhase 2LEO PharmaNCT07013201Written as Delgocitinib cream
- Trial of Delgocitinib 20 mg/g Cream in Subjects With Frontal Fibrosing Alopecia (FFA)Not yet recruitingPhase 2Maryanne Makredes SennaNCT07671157Written as Delgocitinib
- Topical JAK-Inhibition of Early-Stage CTCLNot yet recruitingPhase 2Aarhus University HospitalNCT07781449Written as delgocitinib
- Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen PlanopilarisRecruitingPhase 2Icahn School of Medicine at Mount SinaiNCT07487948Written as Delgocitinib
- The Role of Janus Kinase (JAK) and Voltage-gated Sodium Channels (Nav) on Pain and ItchNot yet recruitingNot applicableAalborg UniversityNCT07203274Written as Delgocitinib cream
- Topical Delgocitinib for Facial VitiligoActive, not recruitingPhase 2Lone SkovNCT07820098Written as Delgocitinib cream
- Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand EczemaCompletedPhase 3LEO PharmaNCT05355818Written as Delgocitinib
- Proof of Concept, Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand EczemaCompletedPhase 2LEO PharmaNCT02664805Written as LEO 124249 ointment
- Clinical Trial to Evaluate Light-induced Skin Reactions After Application of Delgocitinib CreamCompletedPhase 1LEO PharmaNCT04361136Written as Delgocitinib cream
- A Trial to Evaluate the Effect of Delgocitinib on the Heart Rhythm of Healthy PeopleCompletedEarly Phase 1LEO PharmaNCT05050279Written as Delgocitinib capsule
- Clinical Trial to Evaluate UV-light-induced Allergic Skin Reactions After Application of Delgocitinib CreamCompletedPhase 1LEO PharmaNCT04807751Written as Delgocitinib cream
- A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand EczemaCompletedPhase 3LEO PharmaNCT06004050Written as Delgocitinib
- A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand EczemaCompletedPhase 3LEO PharmaNCT05259722Written as Delgocitinib
- Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2)CompletedPhase 3LEO PharmaNCT04872101Written as Delgocitinib cream
- Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 TrialsCompletedPhase 3LEO PharmaNCT04949841Written as Delgocitinib
- Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand EczemaCompletedPhase 3LEO PharmaNCT04871711Written as Delgocitinib cream
- Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand EczemaCompletedPhase 1LEO PharmaNCT05486117Written as Delgocitinib
- Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.CompletedPhase 2LEO PharmaNCT03725722Written as Delgocitinib cream
- Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand EczemaCompletedPhase 2LEO PharmaNCT03683719Written as Delgocitinib cream
Codes
What other systems call delgocitinib · ClinicalTrials.gg INT000743
- MeSH (NLM) C000621572delgocitinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 9L0Q8KK220DELGOCITINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q76620858delgocitinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C171928DelgocitinibOne source FDA
- DrugBank DB16133One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000621572 | delgocitinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 9L0Q8KK220 | DELGOCITINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q76620858 | delgocitinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171928 | Delgocitinib | One source FDA |
| DrugBank | DB16133 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.